Background: Acquired reactive perforating collagenosis (ARPC) is a clinically challenging disease with an unclear pathogenesis.
Objective: To evaluate the efficacy and safety of dupilumab for the treatment of ARPC, and analyze the expression of type 2 inflammation-related molecules in ARPC lesions.
Methods: This retrospective cohort study included 20 patients with ARPC; 10 received dupilumab and 10 received conventional therapy. The efficacy and safety of dupilumab were evaluated at 12 weeks. Immunohistochemical and immunofluorescence analyses of T- and B-cell markers, and type 2 inflammation-related cytokines, were performed on skin samples from ARPC patients, atopic dermatitis (AD) patients, and healthy controls.
Results: Significantly more patients showed improvements in the Investigator Global Assessment score (100% vs. 0%; p < 0.0001) and itching (90%/8.33%, P =.001) in the dupilumab group compared to the conventional group at 12 weeks. There were no adverse effects in the dupilumab group. The ARPC lesions showed enhanced dermal infiltration of CD3+ T-cells, with a predominance of Th2 cells, similar to AD lesions. IL-4 and IL-13 were co-localized with GATA3 in ARPC lesions.
Conclusion: Dupilumab improved ARPC charaterized with type 2 inflammation.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10449391 | PMC |
| http://dx.doi.org/10.3389/fimmu.2023.1240262 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Associated factors and prognostic implications of neutropenia in individuals with HIV/AIDS.
Virol J
January 2025
Department of Hematology, Zhongnan Hospital of Wuhan University, Wuhan, 430071, China.
Background: Neutropenia frequently presents as a hematological manifestation among people living with HIV/AIDS (PLWHA). This study explores the factors associated with neutropenia in PLWHA and its prognostic significance.
Methods: We conducted a retrospective case-control study of the clinical data from 780 cases of individuals living with HIV/AIDS, who were admitted to Zhongnan Hospital of Wuhan University over the period from January 2016 to September 2020.
Diclofenac Enhances the Response of BRAF Inhibitor to Melanoma Through ROS/p38/p53 Signaling.
Clin Exp Pharmacol Physiol
March 2025
Department of Dermatology, Fudan University Huashan Hospital, Shanghai, China.
BRAF inhibitors (BRAFi) represent a cornerstone in melanoma therapy due to their high efficacy. However, the emergence of resistance causes a significant challenge to their clinical utility. This study aims to investigate the potential of diclofenac as a sensitizer for BRAFi therapy in melanoma and to elucidate its underlying mechanism.
View Article and Find Full Text PDFPrediction Models for Post-Stroke Cognitive Impairment: A Systematic Review and Meta-Analysis.
Public Health Nurs
January 2025
School of Nursing, Evidence-Based Nursing Center, Lanzhou University, Lanzhou, China.
Background: Stroke is one of the most serious illnesses worldwide and is the primary cause of acquired disability among adults. Post-stroke cognitive impairment (PSCI) is a complication of stroke that significantly impacts patients' daily activities and social functions. Therefore, developing a risk prediction model for PSCI is essential for identifying and preventing disease progression.
View Article and Find Full Text PDFBiomarkers.
Alzheimers Dement
December 2024
Geriatric Research Education and Clinical Center William S. Middleton VA Hospital, Madison, WI, USA.
Background: Obstructive sleep apnea (OSA) is associated with hypoxia-induced neuronal impairment and dysfunction-key risk factors for the pathogeneses of age-related neurodegenerative diseases such as Alzheimer's disease (AD). This study examined longitudinal associations between OSA severity and CSF biomarkers associated with AD, synaptic dysfunction, and neuroinflammation in a sample of late-middle-aged adults with increased risk for AD.
Method: N=25 cognitively unimpaired adults (64% female, mean age 65.
Background: Cerebrovascular changes are often reported in normal aging, Alzheimer's disease (AD), and vascular dementia (VaD). Cerebral perfusion and cerebrovascular reactivity (CVR) both decrease with dementia compared to healthy aging; as these changes occur prior to symptomatic onset and in distinct brain regions, perfusion and CVR may act as complementary biomarkers of early cerebrovascular changes. These biomarkers can be measured using MRI methods, yielding macrovascular measures of perfusion and CVR.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!